Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Stock Chart & Stats
$1.72
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.72
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$1.39 - $23.37
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$47.85M
Enterprise Value-$9.60M
Total Cash (Recent Filing)$50.90M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta2.80
Next Earnings
Mar 10, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding27,984,040
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.06
Price to Sales (P/S)0.00
P/FCF Ratio-4.94
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$9.80Price Target Upside469.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe company's investigation found no issues with the briquilimab drug product, indicating confidence in the product's quality.
Efficacy And SafetyBriquilimab has shown robust efficacy with clean safety across different studies, providing a consistently solid profile.
Investor ConfidenceAnalyst maintains a Buy recommendation due to the risk/reward profile and the constructive outlook for briquilimab.
Bears Say
Clinical Site IssuesManagement has identified one clinical site where improper injection methods were used, which affected the data and will no longer be used for briquilimab trials.
Enrollment DelaysJSPR has taken a more careful approach to patient enrollment in BEACON, slowing the pace of the enrollment and shifting the timing of the BEACON update.
Patient Enrollment ChallengesCohorts 8 and 9 in the BEACON trial were impacted by poor patient selection, leading to the conclusion that many patients did not have mast cell-driven disease.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $1.39 and its highest was $23.37 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $47.85M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 81 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Nov 10, 2025. The company reported -$1.13 earnings per share for the quarter, beating the consensus estimate of -$1.215 by $0.085.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.72.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 27,984,040 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$1.13 in its last earnings report, beating expectations of -$1.215. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jasper Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.80 (469.77% Upside)
$9.80 (469.77% Upside)
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $347.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.39%
12-Months-Change
Fundamentals
Return on Equity
-191.12%
Trailing 12-Months
Asset Growth
-42.19%
Trailing 12-Months
Company Description
Jasper Therapeutics
Jasper Therapeutics (JSPR) is a biotechnology company focused on the development of innovative therapies for diseases of the hematopoietic system, including immunology and oncology conditions. The company is dedicated to advancing its pipeline of novel therapies aimed at improving patient outcomes by targeting the root causes of these diseases. Jasper Therapeutics' lead product candidate is designed to improve the success and safety of hematopoietic cell transplants, which are critical for treating a variety of life-threatening diseases.
JSPR Stock 12 Month Forecast
Average Price Target
$9.80
▲(469.77% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
6.20% Mutual Funds
55.07% Other Institutional Investors
33.83% Public Companies and Individual Investors